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Radioimmunotherapy (RIT) has demonstrated efficacy with acceptable toxicity leading to
approval in non-Hodgkin’s lymphoma, but has been slower to develop for the treatment of
advanced solid tumors. Prostate cancer (PC) represents a good candidate for RIT based
upon high exposure to circulating antibodies at common disease sites with a specific, highly
expressed cell-surface antigen of prostate-specific membrane antigen. Four phase I and
II trials utilizing 177Lu- or 90Y-J591 have been reported. Long-term toxicity and chemother-
apy administration was analyzed. As expected, the only serious toxicity observed was
myelosuppression. Grade 4 thrombocytopenia occurred in 33.3% without significant hem-
orrhage and grade 4 neutropenia occurred in 17.3% with 0.07% febrile neutropenia. Nearly
all subjects (97.3%) recovered to grade 0 or 1 platelets and all had complete neutrophil
recovery. The majority (81.3%) received chemotherapy at any time, with 61.3% receiving
chemotherapy following RIT.Ten subjects underwent bone marrow biopsies at some point
in their disease course following RIT for low counts; all had diffuse PC infiltration without
evidence of myelodysplasia or leukemia. As expected, myelosuppression occurs following
therapeutic doses of RIT for men with metastatic castration-resistant PC. However, toxic-
ity is predictable and self-limited, with the majority of patients who do not refuse able to
receive cytotoxic chemotherapy following RIT.
Keywords: prostate cancer, radioimmunotherapy, myelotoxicity, prostate-specific membrane antigen, monoclonal
antibody
INTRODUCTION
It is estimated that in year 2013, approximately 238,590 men
will be diagnosed and 29,720 will die due to prostate cancer
(PC) in the United States (1). Despite the effectiveness of hor-
mone therapy, every patient with metastatic disease is currently
incurable and those who live long enough eventually progress to
castration-resistant prostate cancer (CRPC) (2).
Radioimmunotherapy (RIT), using specific monoclonal anti-
bodies (mAbs) or fragments which are radiolabeled (most typically
with beta-emitting particles), has proven quite effective in the
treatment of non-Hodgkin lymphoma (NHL) alone or in combi-
nation with chemotherapy (3–5). RIT for solid tumors has posed
a more difficult challenge for a number of biologic, technical, and
practical reasons (6). In the last decade, significant progress has
been made in the development of RIT for solid tumors. As with
any therapy, emphasis is laid on balancing toxicity and therapeutic
effects.
Metastatic PC is a good candidate for RIT, because it is radio-
responsive and typically develops as small-volume metastatic sites
of disease in marrow and lymph nodes that receive high levels
of circulating antibody. Several clinical trials have focused on or
included subjects with PC (7–16). Importantly, unlike some other
solid tumors, a well-established, specific cell-surface antigen has
been identified: prostate-specific membrane antigen (PSMA) (17–
19). PSMA is an ideal target as it is expressed by nearly all PCs and
is not secreted (17, 19). The expression levels progressively increase
in more poorly differentiated, metastatic, and castration-resistant
cancers (17, 20).
J591 is a deimmunized mAb which specifically binds with high
affinity to the extracellular domain of PSMA (21, 22). In addi-
tion, the PSMA-J591 antibody complex is internalized thereby
delivering any radionuclide or drug conjugated to the antibody to
the interior of the targeted cancer cells (23). We have performed
and reported 4 clinical trials using 177Lu and 90Y labeled J591
(24–28) (Table 1). Based on imaging studies, we have shown that
J591 is able to sensitively and specifically target sites of metasta-
tic PC in both bone and soft tissue (28). As often seen with
RIT, radiolabeled-J591 was well-tolerated and serious toxicity was
confined to predictable, reversible myelosuppression (24, 25, 27,
28). The preliminary efficacy data from initial phase I studies
www.frontiersin.org August 2013 | Volume 3 | Article 214 | 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tagawa et al. Long-term toxicity of anti-PSMA radioimmunotherapy
Table 1 | Radiolabeled-J591 clinical studies summary.
Clinical trial Agent used Number of
subjects
Cumulative
dose (mCi/m2)
Dosing schedule
Phase I dose-escalation study
using 90Y-J591 (24)
111In-J591 and
90Y-J591
29 5–20 111In-J591 for imaging followed by a single 90Y-J591
infusion*
Phase I dose-escalation study
using 177Lu-J591 (25)
177Lu-J591 35 10–75 Single 177Lu-J591 infusion*
Phase II single dose trial (28) 177Lu-J591 47 65–70 Single 177Lu-J591 infusion†
Phase I fractionated dose trial (27) 177Lu-J591 39 40–90 177Lu-J591 infusion followed in 2 weeks by another
at the same dose as first infusion
*Selected subjects with blood count recovery and lack of prostate cancer progression were eligible to receive additional infusions of 177Lu-J591.
†An expansion cohort underwent imaging with 111In-J591 prior to treatment with 177Lu-J591.
has been confirmed in a phase II clinical trial of single-dose
177Lu-J591 (28).
Several RIT studies have demonstrated that, in the absence
of bone marrow or hematopoietic stem cell support, radiation-
induced myelotoxicity is the dose-limiting toxicity (DLT) (29, 30).
Hematologic toxicity is the biggest challenge faced by all radioim-
munotherapeutic agents. The manifestations of myelotoxicity may
be related to the pretreatment peripheral blood cell counts and
bone marrow reserve, which may have been compromised by prior
therapies (29, 31). While the vast majority of patients have spon-
taneous recovery of blood counts, some worry about the ability
to deliver subsequent cytotoxic chemotherapy if needed clinically.
The development of secondary myelodysplastic syndrome (MDS)
or acute myelogenous leukemia (AML) has been reported (32)
and has been estimated to be approximately 2–5% (33). Two stud-
ies have attempted to comprehensively evaluate the risk for MDS
and AML following RIT with either 90Y-ibritumomab or 131I-
tositumomab. These retrospective analyses of large numbers of
patients both showed that RIT did not demonstrate a higher risk
for MDS in comparison with similar patient populations treated
with multiple chemotherapies alone (34, 35).
Long-term outcomes have rarely been reported with solid
tumor RIT. Here, we report the long-term toxicity data in patients
treated with radiolabeled-J591, including bone marrow recovery
and ability to deliver cytotoxic chemotherapy.
MATERIALS AND METHODS
PATIENT POPULATION
For each study, eligible patients had a prior histologic diagno-
sis of PC with evidence progressive metastatic disease as defined
by a serum PSA and/or radiologic studies including bone scan,
computed axial tomography, and/or magnetic resonance imag-
ing despite castrate levels of serum testosterone (i.e., progressive
metastatic CRPC) (24, 25, 27, 28). Patients were required to
have platelet count of≥150,000/mm3, hemoglobin≥ 10, and neu-
trophil count of ≥2,000/mm3. Prior radiation to >25% of the
skeleton and systemic beta-emitting radioisotope therapy (e.g.,
89Sr or 153Sm) was exclusionary. All studies were approved by the
Institutional Review Boards of participating institutions and reg-
istered on clinicaltrials.gov; all subjects provided written informed
consent.
RADIOLABELED ANTIBODIES
Clinical-grade J591 mAb was covalently linked to the chelating
agent, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid
(DOTA) (21). The DOTA-J591 mAb was then radiolabeled with
90Y or 177Lu by incubation at 45°C (±2°C) for 45 min in the
presence of an ammonium acetate buffer (pH 7.0). The final radio-
labeled drug product was purified (when necessary) and filter ster-
ilized before administration into patients as previously described
(24, 25). Radiochemical purity was ≥97% at all cases as con-
firmed by instant thin layer chromatography. The immunoreactive
fraction was always found >0.7 when tested in PSMA+-LNCaP
cells.
TREATMENT AND FOLLOW-UP
Subjects received single or multiple doses of radiolabeled-J591
intravenously at a rate not to exceed 5 mg/min per the particu-
lar protocol on which they were enrolled. Subjects were observed
for a minimum of 12 weeks after their last dose of radiolabeled-
J591 and those patients with stable or responding disease were
observed until disease progression. Routine clinical and labora-
tory assessments (including metabolic profile, PSA, and testos-
terone) were performed at defined intervals. Complete blood
count and platelet counts were monitored at least weekly, with
more frequent monitoring with the onset of grade 3 throm-
bocytopenia or neutropenia. For most studies, white blood cell
growth factors were allowed at the discretion of the investiga-
tor (not allowed in the fractionated dose-escalation study), and
transfusions of platelets were also given at the discretion of the
investigator. Following IRB approval, the number of previous
therapies, the toxicity seen with radiolabeled-J591, the nature
of subsequent therapies, and overall survival (OS) data were
obtained by physician interview, medical record review, and post-
treatment long-term follow-up with patients, families, or other
physicians.
RESULTS
Between October 2000 and August 2012, 150 subjects with
metastatic CRPC received radiolabeled-J591. One hundred and
twenty-one patients received 177Lu-J591 at total doses of 20–
90 mCi/m2 and 29 patients received 90Y-J591 at 5–20 mCi/m2.
Patient baseline demographics are displayed in Table 2.
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Table 2 | Baseline characteristics.
Study Total 90Y-J591 177Lu-J591
Patients, n (%) 150 (100) 29 (19.3) 121 (80.7)
Age, years (range) 70.7 (44.5–96) 70 (48–84.7) 71 (44.5–96)
Prior radiation to any location,
n (%)
77 (51.3) 12 (41.4) 65 (53.7)
Prior radiation to
prostate/prostate bed, n (%)
62 (41.3) 10 (34.5) 52 (42.9)
Cytotoxic chemotherapy prior
to radiolabeled-J591, n (%)
67 (44.6) 14 (48.2) 53 (43.8)
Both chemotherapy and
radiation prior to
radiolabeled-J591, n (%)
35 (23.3) 4 (13.8) 31 (25.6)
Bony metastases, n (%) 129 (86) 20 (69) 109 (90.1)
Pulmonary metastases, n
(%)
23 (15.3) 2 (6.9) 21 (17.4)
Hepatic metastasis, n (%) 12 (8) 1 (3.5) 11 (9.1)
Lymph node metastasis,
n (%)
81 (54) 14 (48.3) 67 (55.4)
ACUTE TOXICITY
Acute toxicity has previously been reported separately for each
study (24, 25, 27, 28). Briefly, without pre-medication, 20.7%
experienced transient grade 1 infusion reactions. Fourteen percent
experienced transient low-grade transaminitis which returned to
baseline in 100%. Platelet count decline was generally seen 2–
3 weeks post infusion with platelet nadir occurring at 4–5 weeks
after administration followed by a recovery phase. Grade 4 throm-
bocytopenia occurred in 33.3% patients without any significant
hemorrhage. Thirty-five patients (23.3%) received platelet trans-
fusion, 5 (17.2%) following 90Y-J591 and 30 (24.8%) following
177Lu-J591. Neutrophil decline typically occurred in parallel with
thrombocytopenia, with nadir similarly 4–5 weeks following treat-
ment. 17.3% experienced grade 4 neutropenia. One subject expe-
rienced grade 3 febrile neutropenia. Seventeen (11.3%) patients
received granulocyte growth factor.
HEMATOLOGIC RECOVERY
All subjects experienced improvement in blood counts follow-
ing RIT induced nadir. Ninety-two percent had complete recov-
ery of platelet counts to grade 0 (i.e., platelet count of at least
150,000/mcL) and 100% experienced recovery of neutrophil count
to Gr 0 (i.e., ANC of at least 2000/mm3). Eight subjects (5.3%)
recovered to grade 1 thrombocytopenia (platelet counts ranging
from 99,000 to 140,000). Four subjects died of progressive PC
prior to platelet recovery from nadir.
Some patients experienced full or partial platelet count recov-
ery followed by subsequent decline. All were associated with
evidence of simultaneous PC progression. Ten underwent bone
marrow aspiration and biopsy confirming PC infiltration overtak-
ing bone marrow (Figure 1). No evidence of MDS or leukemia
was discovered.
The hematologic toxicity seen with radiolabeled-J591 is a
known consequence of RIT. However, patient disease and pre-
vious treatment status can also contribute to amplification of
FIGURE 1 | Representative bone marrow biopsy of a patient with
progressive prostate cancer and decreasing blood counts 3 years after
177Lu-J591 radioimmunotherapy, count recovery, and several
subsequent therapies including chemotherapy. (A) Hematoxylin and
eosin stain at 100× total magnification low power view of bone marrow
with intertrabecular marrow space entirely replaced by metastatic prostate
cancer cells. (B) PSMA – 100× total magnification low power view of same
field of bone marrow replaced by tumor showing PSMA-positivity in tumor
cells (brown staining); scale bars=200 microns. Cytogenetic studies
revealed normal 46, XY male karyotype; normal bone marrow biopsy
control not shown.
such effects. 51.3% of patients treated with radiolabeled-J591 had
history of previous radiation treatment, 44.6% had prior cyto-
toxic chemotherapy, and 23.3% had both prior chemotherapy and
radiation (Table 2).
Grade 4 thrombocytopenia occurred in 40.3% (27/67) of
patients with prior chemotherapy as compared to 27.7% (23/83)
in the no-prior chemotherapy group (p= 0.10); 25.4% (17/67)
with prior chemotherapy received platelet transfusions versus
21.7% (18/83) in the remaining patients (p= 0.59). Grade 4 neu-
tropenia occurred in 17.9% (12/67) with chemotherapy prior to
radiolabeled-J591 treatment versus 19.3% (16/83) in those who
had no previous chemotherapy (p= 0.83) (Table 3).
In those who had received prior radiation, grade 4 thrombocy-
topenia occurred in 33.8% (26/77) as compared to 32.9% (24/73)
in the rest of patients (p= 0.90); 24.7% (19/77) with prior radia-
tion treatment had platelet transfusions versus 21.9% (16/73) in no
previous radiation therapy group (p= 0.69). Grade 4 neutropenia
occurred in 19.5% (15/77) with pre radiolabeled-J591 radiation
treatment versus 17.8% (13/73) in those who had no previous
radiation therapy (p= 0.79).
In those who had received both prior chemotherapy and radia-
tion, 45.7% (16/35) had Grade 4 thrombocytopenia versus 31.7%
(13/41) with neither prior exposure (p= 0.21); 31.4% (11/35)
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Table 3 | Hematologic toxicity by prior therapy.
Prior
chemotherapy
(n=67)
No-prior
chemotherapy
(n=83)
Prior
radiation
(n=77)
No-prior
radiation
(n=73)
Prior chemotherapy
and radiation (n=35)
Neither prior
exposure
(n=41)
Grade 4 thrombocytopenia, n (%) 27 (40.3) 23 (27.7) 26 (33.8) 24 (32.9) 16 (45.7) 13 (31.7)
Platelet transfusion, n (%) 17 (25.4) 18 (21.7) 19 (24.7) 16 (21.9) 11 (31.4) 10 (24.4)
Grade 4 neutropenia, n (%) 12 (17.9) 16 (19.3) 15 (19.5) 13 (17.8) 7 (20) 8 (19.5)
No comparison was statistically significant (p>0.05).
received platelet transfusion with prior chemotherapy and radi-
ation versus 24.4% (10/41) with neither prior exposure (p= 0.49)
(Table 3).
THERAPIES ADMINISTERED AFTER RADIOLABELED-J591
81.3% of patients (122/150) received cytotoxic chemotherapy
either prior to or after radiolabeled-J591. In review of long-term
follow-up data, 92 (61.3%) received cytotoxic chemotherapy post
radiolabeled-J591 infusion. Sixty-one percent (56/92) patients
who received chemotherapy post RIT were chemo-naive prior to
treatment and 39% (36/92) received chemotherapy both before
and after RIT. 13.3% (20/150) of patients received investigational
treatment following RIT, 24.6% (37/150) had no active treatment,
13.3% (20/150) were deemed chemotherapy eligible by their physi-
cians, but declined subsequent chemotherapy and 12% (18/150)
enrolled in hospice or died before starting a new treatment.
DISCUSSION
Prostate cancer offers a model for the investigation and devel-
opment of RIT in solid tumors, given the restricted, high-level
of expression of PSMA and the availability of a specific, well-
tolerated mAb (J591). As myelosuppression and subsequent bone
marrow recovery as well as the theoretical inability to tolerate sub-
sequent cytotoxic chemotherapy are potential issues with RIT, we
analyzed our long-term results with radiolabeled-J591. It should
be noted that this analysis included radiolabeled-J591 adminis-
tered across a number of different cumulative doses in phase I
and II studies, including a prospective fractionated dose schedule
(Table 1).
The vast majority of subjects who received radiolabeled-J591
had complete (i.e., grade 0) or near-complete (grade 1) recov-
ery of neutrophil (100%) and platelet (97.3%) counts. Those that
did not experience complete recovery or who experienced sub-
sequent decline in blood counts had concomitant progression of
PC. Those with bone marrow biopsies at subsequent count decline
had diffuse PC marrow infiltration and none had evidence of MDS
or leukemia. As some have proposed that prior treatment might
influence subsequent bone marrow reserve and the ability to toler-
ate RIT, (31) we analyzed by previous exposure to chemotherapy
and/or radiation. There was a trend for more grade 4 thrombo-
cytopenia in those with both prior chemotherapy and radiation,
but no clear differences in those who had received either previous
chemotherapy or radiation.
Because of the myelosuppression observed in patients treated
with radiolabeled-J591, a further concern is whether patients
can tolerate subsequent therapeutic interventions if needed for
disease progression after RIT. The available data suggest that
patients treated with radiolabeled-J591 can tolerate subsequent
therapies. The majority (92 of 150, 61.3%) of patients received
cytotoxic chemotherapy after radiolabeled-J591, including doc-
etaxel and cabazitaxel. Although two of the four studies were
completed prior to the approval of docetaxel for metastatic
CRPC, 95 of 150 (63.3%) received docetaxel at any time, a
favorable number compared to the estimated third of men
with metastatic CRPC ever receiving docetaxel according to a
survey of urologists and oncologists in the era prior to the
approval of newer agents such as Sipuleucel-T, Abiraterone, and
Enzalutamide. Another concern might be a theoretic possibil-
ity of poorer chemotherapy tolerance in the setting of prior
RIT. While this cannot be completely addressed in a retro-
spective study, patients who received docetaxel at any time
following radiolabeled-J591 received a median of 23 weeks of
chemotherapy (range 10–68) (i.e., 7–8 cycles) and those who
received cabazitaxel received a median of 18 weeks (range 17–
36) (i.e., 5–6 cycles), both within range of general community
standards.
One of the most serious concerns about RIT is its potential
to lead to secondary malignancies, particularly MDS/AML. The
long-term data following RIT of solid tumors is limited, in part for
the practical reason of populations that have been studied (gen-
erally late stage, refractory cancers). In this study, subjects were
treated over a 12-year period with median time from treatment of
7.8 years (range 0.7–12.7); censored for loss to follow-up or death,
median follow-up for this analysis was 16.6 months (range 0.5–
133.9). The estimated median survival for the population based
upon nomogram analysis is 15 months (median Halabi score 145,
range 62–196) (36). As solid tumor RIT moves earlier in the dis-
ease process and as median survival for advanced solid tumors
increases with more successful therapy, long-term toxicity follow-
up is needed. More data exist following RIT for NHL. With a
median 10-year follow-up, Kaminski et al. reported a single case of
MDS out of 76 previously untreated patients who received a single
treatment with 131I-tositumomab (37). Czuczman et al. reviewed
the records of 746 patients treated with 90Y-ibritumomab tiux-
etan with a median follow-up of 4.5 years and found a total of
2.5% of patients developed MDS at a median of nearly 2 years
following RIT (35). This corresponded to an annualized MDS
rate of 0.7% per year following RIT. The expected annual rate
of treatment-related MDS for NHL patients receiving systemic
therapy alone or in combination with rituximab is approximately
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1% per year (38, 39). Higher doses of therapy may pose greater
risk. Recently, Guidetti et al. published prospective data on devel-
opment of MDS/AML in NHL patients receiving myeloablative
doses of 90Y-Ibritumomab tiuxetan. Among 52 patients with a
median follow-up of 49 months, the 5-year cumulative incidence
of MDS/AML was 8.29% (40). This incidence is significantly
higher than previously reported with lower doses, but the stud-
ied population consisted of subjects receiving significantly higher
doses of RIT than used for solid tumors and a matched-pair
analysis of patients receiving myeloablative chemotherapy condi-
tioning instead of RIT revealed a similar 8.05% 5-year cumulative
incidence of MDS/AML.
Taken together, although there have been few prospective stud-
ies designed specifically to assess the risk of development of
MDS/AML following RIT for NHL, with significant follow-up,
the use of RIT does not appear to significantly increase the risk of
secondary MDS above the risk of chemotherapy alone in patients
with NHL. Should cases of MDS or leukemia be discovered with
radiolabeled-J591 or other RIT for PC, it will be important to
understand that as in NHL, additional therapies may be associated
with MDS/AML and there is a de novo incidence in an elderly male
population (35, 41, 42).
CONCLUSION
Systemic targeted radiation with RIT has therapeutic promise in
advanced solid tumors, in particular for radiosensitive tumors
such as PC with a selective and specific cell-surface antigen such
as PSMA and an available antigen-specific, non-immunogenic
mAb such as J591. Using beta-emitting radionuclides at thera-
peutic doses, myelosuppression is expected. However, toxicity is
predictable and usually self-limited, with the majority of patients
who do not refuse able to receive chemotherapy. As the use of
RIT becomes more attractive across diseases with the develop-
ment of newer, more specific mAbs or peptides, studies examining
long-term toxicity are warranted.
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